Literature DB >> 24849045

Social and Clinical Determinants of Contralateral Prophylactic Mastectomy.

Sarah T Hawley1, Reshma Jagsi2, Monica Morrow3, Nancy K Janz4, Ann Hamilton5, John J Graff6, Steven J Katz7.   

Abstract

IMPORTANCE: The growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as having breast cancer has raised concerns about potential for overtreatment. Yet, there are few large survey studies of factors that affect women's decisions for this surgical treatment option.
OBJECTIVE: To determine factors associated with the use of CPM in a population-based sample of patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: A longitudinal survey of 2290 women newly diagnosed as having breast cancer who reported to the Detroit and Los Angeles Surveillance, Epidemiology, and End Results registries from June 1, 2005, to February 1, 2007, and again 4 years later (June 2009 to February 2010) merged with Surveillance, Epidemiology, and End Results registry data (n = 1536). Multinomial logistic regression was used to evaluate factors associated with type of surgery. Primary independent variables included clinical indications for CPM (genetic mutation and/or strong family history), diagnostic magnetic resonance imaging, and patient extent of worry about recurrence at the time of treatment decision making. MAIN OUTCOMES AND MEASURES: Type of surgery received from patient self-report, categorized as CPM, unilateral mastectomy, or breast conservation surgery.
RESULTS: Of the 1447 women in the analytic sample, 18.9% strongly considered CPM and 7.6% received it. Of those who strongly considered CPM, 32.2% received CPM, while 45.8% received unilateral mastectomy and 22.8% received breast conservation surgery (BCS). The majority of patients (68.9%) who received CPM had no major genetic or familial risk factors for contralateral disease. Multivariate regression showed that receipt of CPM (vs either unilateral mastectomy or breast conservation surgery) was significantly associated with genetic testing (positive or negative) (vs UM, relative risk ratio [RRR]: 10.48; 95% CI, 3.61-3.48 and vs BCS, RRR: 19.10; 95% CI, 5.67-56.41; P < .001), a strong family history of breast or ovarian cancer (vs UM, RRR: 5.19; 95% CI, 2.34-11.56 and vs BCS, RRR: 4.24; 95% CI, 1.80-9.88; P = .001), receipt of magnetic resonance imaging (vs UM RRR: 2.07; 95% CI, 1.21-3.52 and vs BCS, RRR: 2.14; 95% CI, 1.28-3.58; P = .001), higher education (vs UM, RRR: 5.04; 95% CI, 2.37-10.71 and vs BCS, RRR: 4.38; 95% CI, 2.07-9.29; P < .001), and greater worry about recurrence (vs UM, RRR: 2.81; 95% CI, 1.14-6.88 and vs BCS, RRR: 4.24; 95% CI, 1.80-9.98; P = .001). CONCLUSIONS AND RELEVANCE: Many women considered CPM and a substantial number received it, although few had a clinically significant risk of contralateral breast cancer. Receipt of magnetic resonance imaging at diagnosis contributed to receipt of CPM. Worry about recurrence appeared to drive decisions for CPM although the procedure has not been shown to reduce recurrence risk. More research is needed about the underlying factors driving the use of CPM.

Entities:  

Mesh:

Year:  2014        PMID: 24849045      PMCID: PMC4703398          DOI: 10.1001/jamasurg.2013.5689

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  36 in total

1.  Perceptions of care coordination in a population-based sample of diverse breast cancer patients.

Authors:  Sarah T Hawley; Nancy K Janz; Sarah E Lillie; Christopher R Friese; Jennifer J Griggs; John J Graff; Ann S Hamilton; Sarika Jain; Steven J Katz
Journal:  Patient Educ Couns       Date:  2010-11-12

Review 2.  Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.

Authors:  Abenaa M Brewster; Patricia A Parker
Journal:  Oncologist       Date:  2011-06-14

3.  When is contralateral mastectomy warranted in unilateral breast cancer?

Authors:  Mitchel Barry; Virgilio Sacchini
Journal:  Expert Rev Anticancer Ther       Date:  2011-08       Impact factor: 4.512

4.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

Authors:  Tari A King; Rita Sakr; Sujata Patil; Inga Gurevich; Michelle Stempel; Michelle Sampson; Monica Morrow
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

5.  Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Authors:  Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

6.  Racial/ethnic disparities in knowledge about risks and benefits of breast cancer treatment: does it matter where you go?

Authors:  Sarah T Hawley; Angela Fagerlin; Nancy K Janz; Steven J Katz
Journal:  Health Serv Res       Date:  2008-04-01       Impact factor: 3.402

Review 7.  Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

Authors:  Todd Tuttle; Elizabeth Habermann; Anasooya Abraham; Timothy Emory; Beth Virnig
Journal:  Expert Rev Anticancer Ther       Date:  2007-08       Impact factor: 4.512

8.  Racial/ethnic differences in adequacy of information and support for women with breast cancer.

Authors:  Nancy K Janz; Mahasin S Mujahid; Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; Steven J Katz
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

9.  Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer.

Authors:  Amanda K Arrington; Stephanie L Jarosek; Beth A Virnig; Elizabeth B Habermann; Todd M Tuttle
Journal:  Ann Surg Oncol       Date:  2009-08-04       Impact factor: 5.344

10.  Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients.

Authors:  Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; John J Graff; Nancy K Janz; Monica Morrow; Reshma Jagsi; Barbara Salem; Steven J Katz
Journal:  J Natl Cancer Inst       Date:  2009-08-31       Impact factor: 13.506

View more
  56 in total

1.  Tradeoffs Associated With Contralateral Prophylactic Mastectomy in Women Choosing Breast Reconstruction: Results of a Prospective Multicenter Cohort.

Authors:  Adeyiza O Momoh; Wess A Cohen; Kelley M Kidwell; Jennifer B Hamill; Ji Qi; Andrea L Pusic; Edwin G Wilkins; Evan Matros
Journal:  Ann Surg       Date:  2017-07       Impact factor: 12.969

2.  Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Karen Sepucha; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Meghan E Meyer; Lidia Schapira; Steven E Come; Virginia F Borges; Mehra Golshan; Eric P Winer; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2015-05-01       Impact factor: 5.344

Review 3.  Evolution and update on current devices for prosthetic breast reconstruction.

Authors:  Kristina O'Shaughnessy
Journal:  Gland Surg       Date:  2015-04

4.  Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis.

Authors:  Thomas A D'Agostino; Abenaa M Brewster; Susan K Peterson; Isabelle Bedrosian; Patricia A Parker
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

Review 5.  Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients.

Authors:  Giacomo Montagna; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-28       Impact factor: 4.512

6.  Factors Affecting Surgical Decisions in Newly Diagnosed Young Women with Early-Stage Breast Cancer.

Authors:  Shoshana M Rosenberg; Mary L Greaney; Andrea F Patenaude; Ann H Partridge
Journal:  J Adolesc Young Adult Oncol       Date:  2019-04-03       Impact factor: 2.223

7.  Breast cancer: why do women opt for contralateral prophylactic mastectomy?

Authors:  Aron Goldhirsch; Shari Gelber
Journal:  Nat Rev Clin Oncol       Date:  2014-07-08       Impact factor: 66.675

8.  B-Sure: a randomized pilot trial of an interactive web-based decision support aid versus usual care in average-risk breast cancer patients considering contralateral prophylactic mastectomy.

Authors:  Sharon L Manne; Barbara L Smith; Sara Frederick; Anna Mitarotondo; Deborah A Kashy; Laurie J Kirstein
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

9.  Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study.

Authors:  L Findlay-Shirras; I Lima; G Smith; M Clemons; A Arnaout
Journal:  Breast Cancer Res Treat       Date:  2020-10-30       Impact factor: 4.872

10.  Contralateral Prophylactic Mastectomy: Challenging Considerations for the Surgeon.

Authors:  Peter Angelos; Isabelle Bedrosian; David M Euhus; Virginia M Herrmann; Steven J Katz; Andrea Pusic
Journal:  Ann Surg Oncol       Date:  2015-08-11       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.